Skip to Content

Acalabrutinib ± obinutuzumab demonstrates durable disease control and tolerability in treatment-naïve CLL

In this MEDtalk Talha Munir, MD, Consultant Haematologist, St James’s Hospital, Leeds, UK, presents the five-years updated analysis of the phase III ELRVATE-TN trial. In this trial, treatment-naïve patients with CLL are treated with acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil. As indicated, the study demonstrates durable disease control and tolerability.

Talha Munir

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top